FDA approvals include two new AIDS drugs, pediatric labeling for two protease inhibitors.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D020008:Delavirdine; D017277:Drug Approval; D004348:Drug Labeling; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors; D006801:Humans; D007211:Indoles; D007546:Isoquinolines; D019888:Nelfinavir; D010879:Piperazines; D018894:Reverse Transcriptase Inhibitors; D019438:Ritonavir; D013451:Sulfonic Acids; D014481:United States; D014486:United States Food and Drug Administration
D017320:HIV Protease Inhibitors; D007211:Indoles; D007546:Isoquinolines; D010879:Piperazines; D018894:Reverse Transcriptase Inhibitors; D013451:Sulfonic Acids; D020008:Delavirdine; D019888:Nelfinavir; D019438:Ritonavir